Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets.
Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played an integral role in this transaction and will provide the necessary corporate support, exchange connectivity, collateral management and custodial services.
Strengthening BCP’s Market Position
This acquisition significantly expands BCP’s Bitcoin trading and yield generation capabilities, reinforcing its position as a leading provider of institutional-grade, risk managed Bitcoin yield solutions. By integrating specialized expertise in Bitcoin derivatives and volatility strategies, with a powerful execution and real time risk analytics platform, BCP will capture alternative yield opportunities across both stable and highly volatile market environments.
A Strategic Fit for the Next Phase of Institutional Bitcoin Adoption
The transaction is aligned with BCP’s broader strategy to develop a premier institutional platform for digital asset trading, yield generation and structured solutions. By incorporating these new capabilities, BCP strengthens its ability to deliver:
- Yield-enhancing derivatives strategies for Bitcoin treasury (including corporate and DAO treasuries), asset-management, and corporate clients, offering an alternative and reliable source of yield on their Bitcoin holdings.
- Powerful execution infrastructure with embedded market risk solutions designed to support institutional-grade trading of Bitcoin and operational oversight.
PeterPaul Pardi, Managing Partner of Blockstream Capital Partners, said: “Core to the growth of our business is industry-leading talent, proprietary trading strategies and adding to our best-in-class risk management. Deepak brings a rare blend of institutional TradFi rigor and hands-on digital assets trading expertise. By acquiring Numeus’s trading business, we’re adding proven crypto-derivatives and volatility capabilities that institutions increasingly demand, while strengthening our platform offering.”
Deepak Gulati, Co-Chief Investment Officer of Blockstream Capital Management, commented: “The Blockstream Capital Partners team has the ambition, expertise and platform to set the standard for how institutions access and manage their Bitcoin exposure, and I’m thrilled to help accelerate that build.”
Paul Frost-Smith, CEO at Komainu, said: “We’re committed to advancing both innovation and institutional adoption across the Bitcoin ecosystem. BCP is an important partner in that mission, and we’re excited to deepen the relationship as we continue developing and launching new Bitcoin-centric products and services.”
This transaction builds upon BCP’s December 2025 acquisition of Corbiere Capital Management, a Jersey-based equities hedge fund manager led by Rodrigo Rodriguez. Numeus Group is also looking forward to building future value through strategic collaboration with BCP, a leader in the crypto industry.
About BCP Group
Blockstream Capital Partners (BCP) is an investment group of Bitcoin pioneers driving the convergence of Bitcoin and institutional finance. Affiliated with Dr. Adam Back, CEO of Blockstream, the global leader in Bitcoin and blockchain infrastructure, BCP brings together early Bitcoin investors from before the first halving and veteran institutional finance leaders with decades of experience managing global capital.
BCP invests across asset classes - venture capital, private and public equity, credit, real estate, and insurance - and across the entire stack of Bitcoin finance: from infrastructure (including trading, custody, payments, and settlement) to Bitcoin-based applications and financial instruments. Its approach reflects the same philosophy that defines Blockstream: an uncompromising commitment to building the financial infrastructure of the future and a long-term conviction in Bitcoin.
BCP operates a comprehensive investment platform offering institutional-grade Bitcoin solutions designed to deliver Bitcoin-referenced returns and long-term value for investors. With a global presence in key financial hubs, BCP is positioned to serve leading institutional allocators worldwide.
About Numeus Group
Numeus is a digital asset investment firm founded in 2021 by a team of institutional trad-finance and blockchain experts with a team of 33 today across Switzerland, New York, London, and Mauritius. Its asset management division, Forteus, offers absolute-return and directional strategies under an FCA-regulated framework and maintains a strategic partnership with Schroders plc.
About Komainu
Komainu is the institutional gateway for digital assets, headquartered in Jersey, with offices in London, Dubai, and Singapore. Offering bank-grade infrastructure for institutional investors, Komainu provides seamless, connected and secure services with multi-jurisdictional regulatory oversight, merging expertise from traditional financial services with leading security standards for the next generation of institutional digital asset custody, servicing & financing. Komainu (Jersey) Limited is regulated by the Jersey Financial Services Commission. Komainu MEA FZE is regulated by the Dubai Virtual Assets Regulatory Authority.
For more information, visit https://www.komainu.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260109215098/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom